TMDX · Analysis updated Nov 10, 2026, 6:00 PM ET

Why is TransMedics Group, Inc. Common Stock (TMDX) stock moving?

TransMedics reported Q3 2026 results on Nov 5 that beat consensus: revenue of $203.0M rose 41% (35% organic), adjusted EPS was $0.51 against $0.29 expected, and full-year 2026 revenue guidance rose to $764-774M, including about $14M from PAD Aviation. Management highlighted record revenue and case volume despite seasonal weakness, and pointed to ENHANCE Heart Part B and DENOVO Lung trials, a European launch in Italy, the Netherlands and Belgium, and OCS Kidney first-in-human in 2H 2027. The stock was volatile around the print: it closed at $72.76 on Nov 4 on 2.47M shares, fell to $68.98 on Nov 5, then jumped to $88.24 on Nov 6 on 3.95M shares, about five times the October average, as Canaccord ($120) and Needham ($110) raised targets. It rose further to a $95.30 high on Nov 9 and closed at $90.95 on Nov 10, about 7% below the $97.56 intraday high, with volume falling to 1.63M. UBS raised its target to $88 but kept a Neutral rating, so the shares now trade above that target. Benzinga's headline guidance range ($750-760M) conflicts with the company's release ($764-774M); the release figure is used here. The stock has risen roughly 35% since Nov 3, so much of the good news is priced in, and the trial and European milestones that drive later upside are still ahead.

News behind the analysis

About TransMedics Group, Inc. Common Stock

Healthcare · Medical devices (organ transplant technology)

TransMedics, based in Andover, Massachusetts, makes the Organ Care System (OCS), a portable machine that keeps donor hearts, lungs and livers warm, perfused and working while they're moved between hospitals, instead of storing them on ice. It's unusual because it also runs a turnkey National OCS Program (NOP): its own surgeons find and recover organs, and its own fleet of aircraft flies them to the transplant center.

How it makes money

Most revenue comes from US transplant centers, which pay for single-use OCS disposable sets and related clinical services each time an organ is preserved. Liver is the largest organ segment, followed by heart and lung. A growing share, roughly a fifth (about $41M of about $190M in Q2 2026), comes from TransMedics Logistics, which charges for organ transport on its aviation fleet. In 2026 the company guided to roughly $737–757M in revenue (about 22–25% growth), with Europe (starting in Italy) and new kidney and next-generation heart and lung programs as future expansion areas.

What usually moves TMDX

Similar companies

ISRG, PEN, LMAT, IRTC, INSP

All stock analyses · Stock market today

This analysis is for information only and is not financial advice. It relies on the news and market data provided, which may be incomplete. Verify the information and consult a qualified adviser before investing.